Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study - Université de Picardie Jules Verne Accéder directement au contenu
Article Dans Une Revue Journal of Crohn's and Colitis Année : 2022

Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study

Fichier non déposé

Dates et versions

hal-03665861 , version 1 (12-05-2022)

Identifiants

  • HAL Id : hal-03665861 , version 1
  • WOS : 000778573400527

Citer

A. Buisson, M. Nachury, M. Reymond, Clara Yzet, P. Wils, et al.. Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study. Journal of Crohn's and Colitis, 2022, 16 (1), pp.I393-I394. ⟨hal-03665861⟩
119 Consultations
0 Téléchargements

Partager

Gmail Mastodon Facebook X LinkedIn More